Whole-genome immunoinformatic analysis of f. tularensis: Predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Zvi, Anat ^a   Rotem, Shahar ^a   Bar Haim, Erez ^a   Cohen, Ofer ^a   Shafferman, Avigdor ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; EPITOPE; HLA ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BACTERIAL GENOME; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FRANCISELLA TULARENSIS; GENE CLUSTER; GENE MAPPING; GENE SEQUENCE; GENETIC ANALYSIS; IMMUNOINFORMATIC ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; SPLEEN CELL; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; MUS;

ANIMALS; EPITOPES; FRANCISELLA TULARENSIS; GENOME, BACTERIAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79956322512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020050     Document Type: Article

References (59)

1. Cox MA, Zajac AJ, (2010) Shaping successful and unsuccessful CD8 T cell responses following infection. J Biomed Biotechnol 2010: 159152.
2. Huster KM, Stemberger C, Busch DH, (2006) Protective immunity towards intracellular pathogens. Curr Opin Immunol 18: 458-464.
3. Seder RA, Hill AV, (2000) Vaccines against intracellular infections requiring cellular immunity. Nature 406: 793-798.
4. Titball RW, (2008) Vaccines against intracellular bacterial pathogens. Drug Discov Today 13: 596-600.
5. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S, (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
6. Hepburn MJ, Simpson AJ, (2008) Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther 6: 231-240.
7. Sjostedt A, (2006) Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect 8: 561-567.
8. Titball RW, Petrosino JF, (2007) Francisella tularensis genomics and proteomics. Ann N Y Acad Sci 1105: 98-121.
9. Pechous RD, McCarthy TR, Zahrt TC, (2009) Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev 73: 684-711.
10. Zvi A, Ariel N, Shafferman A, (2010) Data mining, bioinformatic and immunoinformatic analyses of Francisella tularensis Schu S4 genome in search for novel vaccine candidates. In: Shafferman A, Ordentlich A, Velan B, editors. The challenge of highly pathogenic microorganisms- mechanism of virulence and novel medical countermeasures pp. 229-243 Springer, London-NewYork.
11. Barry EM, Cole LE, Santiago AE, (2009) Vaccines against tularemia. Hum Vaccin 5: 832-838.
12. Conlan JW, (2007) Vaccines against Francisella tularensis. Ann NY Acad Sci 1105: 325-350.
13. Conlan W, Sjostedt A, (2010) Novel live vaccine candidates against airborne Francisella tularensis. In: Shafferman A, Ordentlich A, Velan B, editors. The challenge of highly pathogenic microorganisms- mechanism of virulence and novel medical countermeasures pp. 213-218 Springer, London-NewYork.
14. Griffin KF, Oyston PC, Titball RW, (2007) Francisella tularensis vaccines. FEMS Immunol Med Microbiol 49: 315-323.
15. Mann BJ, Ark NM, (2009) Rationally designed tularemia vaccines. Expert Rev Vaccines 8: 877-885.
16. McMurry JA, Moise L, Gregory SH, De Groot AS, (2007) Tularemia vaccines- an overview. Med Health R I 90: 311-314.
17. Oyston PC, (2009) Francisella tularensis vaccines. Vaccine 27 (Suppl 4): D48-51.
18. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
19. Bambini S, Rappuoli R, (2009) The use of genomics in microbial vaccine development. Drug Discov Today 14: 252-260.
20. Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ, (2000) Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates. Vaccine 19: 601-612.
21. Chitlaru T, Shafferman A, (2009) Proteomic studies of Bacillus anthracis. Future Microbiol 4: 983-998.
22. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
23. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, et al. (2002) Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70: 368-379.
24. Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, et al. (2001) Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19: 4135-4142.
25. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, et al. (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69: 1593-1598.
26. Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A, (2008) Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics 1: 18.
27. Shafferman A, Gat O, Ariel N, Chitlaru T, Grosfeld H, et al. (2010) Reverse vaccinology in Bacillus anthracis. In: Shafferman A, Ordentlich A, Velan B, editors. The challenge of highly pathogenic microorganisms- mechanism of virulence and novel medical countermeasures pp. 295-306 Springer, London-NewYork.
28. Lundegaard C, Hoof I, Lund O, Nielsen M, (2010) State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res 6 (Suppl 2): S3.
29. Lundegaard C, Lund O, Buus S, Nielsen M, (2010) Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 130: 309-318.
30. Nielsen M, Lund O, Buus S, Lundegaard C, (2010) MHC class II epitope predictive algorithms. Immunology 130: 319-328.
31. Ginodi I, Vider-Shalit T, Tsaban L, Louzoun Y, (2008) Precise score for the prediction of peptides cleaved by the proteasome. Bioinformatics 24: 477-483.
32. Nielsen M, Lundegaard C, Lund O, Kesmir C, (2005) The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57: 33-41.
33. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG, (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171: 1741-1749.
34. Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, et al. (2007) Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol 178: 6814-6820.
35. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V, (2008) Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9: 8.
36. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V, (2008) Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 9 (Suppl 12): S22.
37. Lundegaard C, Nielsen M, Lund O, (2006) The validity of predicted T-cell epitopes. Trends Biotechnol 24: 537-538.
38. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, et al. (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8: 424.
39. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, et al. (2008) Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori. Hum Vaccin 4: 219-223.
40. McMurry JA, Kimball S, Lee JH, Rivera D, Martin W, et al. (2007) Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med 7: 351-368.
41. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, et al. (2007) Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 25: 3179-3191.
42. Sette A, Rappuoli R, (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33: 530-541.
43. Davies V, Vaughan K, Damle R, Peters B, Sette A, (2009) Classification of the universe of immune epitope literature: representation and knowledge gaps. PLoS One 4: e6948.
44. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, et al. (2006) A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24: 817-819.
45. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, et al. (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153: 5586-5592.
46. Yewdell JW, Bennink JR, (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88.
47. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, et al. (2010) The immune epitope database 2.0. Nucleic Acids Res 38: D854-862.
48. Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, et al. (2003) Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol 171: 4140-4148.
49. Surman S, Lockey TD, Slobod KS, Jones B, Riberdy JM, et al. (2001) Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A 98: 4587-4592.
50. Kim SK, DeMars R, (2001) Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr Opin Immunol 13: 429-436.
51. Lucchiari-Hartz M, Lindo V, Hitziger N, Gaedicke S, Saveanu L, et al. (2003) Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc Natl Acad Sci U S A 100: 7755-7760.
52. Shankar P, Fabry JA, Fong DM, Lieberman J, (1996) Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes. Immunol Lett 52: 23-30.
53. Valmori D, Levy F, Godefroy E, Scotto L, Souleimanian NE, et al. (2007) Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 122: 163-172.
54. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76: 8757-8768.
55. Schmid BV, Kesmir C, de Boer RJ, (2009) The distribution of CTL epitopes in HIV-1 appears to be random, and similar to that of other proteomes. BMC Evol Biol 9: 184.
56. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, et al. (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36: W509-512.
57. Krogh A, Larsson B, von Heijne G, Sonnhammer EL, (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305: 567-580.
58. Bendtsen JD, Nielsen H, von Heijne G, Brunak S, (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783-795.
59. Kyte J, Doolittle RF, (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157: 105-132.